Vilanterol-d4 (trifenatate)

Vilanterol-d4 (trifenatate)

• CAS Number: 2021249-10-3
• UNSPSC Description: Vilanterol-d4 (trifenatate) is deuterium labeled Vilanterol (trifenatate). Vilanterol trifenatate (GW642444 trifenatate) is a long-acting β2-adrenoceptor (β2-AR) agonist with inherent 24-hour activity. The pEC50s for β2-AR, β1-AR and β3-AR are 10.37, 6.98 and 7.36, respectively.
• Target Antigen: Adrenergic Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Inflammation/Immunology; Endocrinology
• Solubility: 10 mM in DMSO
• Smiles: OC(C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=O.ClC(C=CC=C4Cl)=C4COC([2H])([2H])C([2H])([2H])OCCCCCCNC[C@@H](C5=CC(CO)=C(C=C5)O)O
• Molecular Weight: 778.79
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100.|[3]Kempsford R, et al. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-|[4]Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported